title: "Moderate intensive insulin therapy" is associated with remission of high intracranial pressure in patients with vascular or infectious central nervous system diseases.
abstract: Intensive insulin therapy (IIT), targeting blood glucose between 80 mg/dL and 110 mg/dL ("strict IIT"), has been associated with rapid remission of high intracranial pressure (ICP), but its use is limited due to a high risk of hypoglycemia. The aim of this retrospective study was to assess whether "moderate IIT" (target range for blood glucose: 80-140 mg/dL) could have the same beneficial effect on ICP with a lower risk of hypoglycemia. We retrospectively analyzed the records of 64 patients with high ICP due to vascular or infectious central nervous system diseases. Patients treated with moderate IIT (n=32) after 2005 were compared with patients treated with a conventional approach (n=32, target <180 mg/dL) before 2005. We assessed daily ICP during the first 14 days. Secondary endpoints were the rate of hypoglycemic events and outcome. ICP was significantly lower during the second week in patients treated with moderate IIT (mean±standard deviation [SD] daily ICP on days 8-14: 16±5 mmHg compared to 12±4 mmHg, p<0.001). The risk of hypoglycemic events (<40 mg/dL) did not differ significantly between the groups (0 vs. 1 patient, p=0.5). Moderate IIT is associated with remission of high ICP. In contrast to strict IIT, its use seems not to be limited by an increased risk of severe hypoglycemia.
authors.affiliation: Department of Neurology, Ludwig-Maximilians-University, Klinikum Großhadern, Marchioninistraße 15, Munich 81377, Germany. tobias.birnbaum@med.uni-muenchen.de
authors.forename: Tobias
authors.initials: T
authors.lastname: Birnbaum
authors.forename: Stephanie Pia
authors.initials: SP
authors.lastname: Schmid
authors.forename: Berend
authors.initials: B
authors.lastname: Feddersen
authors.forename: Christoph Josef
authors.initials: CJ
authors.lastname: Schankin
authors.forename: Andreas
authors.initials: A
authors.lastname: Straube
mesh_terms: D000328:Adult; D000368:Aged; D002494:Central Nervous System Infections / Q000150:complications / Q000378:metabolism / Q000503:physiopathology; D002561:Cerebrovascular Disorders / Q000150:complications / Q000378:metabolism / Q000503:physiopathology; D005260:Female; D006801:Humans; D006943:Hyperglycemia / Q000188:drug therapy / Q000503:physiopathology; D007004:Hypoglycemic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D007328:Insulin / Q000008:administration & dosage* / Q000009:adverse effects; D019586:Intracranial Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies
chemical_list: D007004:Hypoglycemic Agents; D007328:Insulin